The development of multimodality and targeted treatment strategies has improved the prognosis of patients with gastrointestinal cancers. Not all patients, however, benefit equally from these treatment approaches, and the ability to predict who will respond positively to a treatment type is of particular importance. This Review discusses the role of biomarkers and metabolic imaging approaches in the prediction of response to therapy early on in treatment.
- Ken Herrmann
- Axel Walch
- Matthias PA Ebert
